Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10065


Purpose:

The purpose of this study is to find out if men, with low-risk prostate, can have the small amount of cancer within their prostate removed by freezing, called Focal Cryoablation or Cryotherapy.


Criteria:

A two-step consenting process will be in place for all patients being enrolled to this study. The two-step method is necessary because all patients being enrolled will need to have a repeat transrectal biopsy after meeting the initial study requirements. The two step consent process would enroll patients considering focal cryotherapy into the initial part of the study (QOL assessment at baseline, PCA3 test, and repeat biopsy); those deemed eligible after the re-staging biopsy would be consented to participate in the remainder of the study (focal cryotherapy, QOL studies, repeat biopsy at 6 months for efficacy, PCA3 test). First Step Enrollment Inclusion Criteria: - Men ≥ 21 years of age with a life expectancy estimated to be > 10-years. - Diagnosis of adenocarcinoma of the prostate and confirmed by MSKCC review - No prior treatment for prostate cancer - ECOG performance status of 0 or 1 - Prostate cancer clinical stage T1c-T2a - PSA < 10ng/mL (this will be the PSA level prompting the prostate biopsy) - Prostate Size <60 cc on transrectal ultrasound - Exclusion Criteria: - Medically unfit for anesthesia - Histology other than adenocarcinoma - Men who have received any hormonal manipulation (antiandrogens; LHRH agonists) within the previous 6 months - Men who are currently receiving anticoagulant drugs (e.g.: Coumadin, warfarin) Second Step Enrollment Inclusion Criteria: - Repeat transrectal prostate biopsy that must meet the following parameters: - Minimum of 12 biopsy cores - No Biopsy Gleason grade 4 or 5 - Unilateral cancer (only right-sided or left-sided, not bilateral) - No more than 50% cancer in any one biopsy core - No more than 25% of cores containing cancer Exclusion Criteria: - Medically unfit for anesthesia - Histology other than adenocarcinoma - Men who have received any hormonal manipulation (antiandrogens; LHRH agonists) within the previous 6 months - Men who are currently receiving anticoagulant drugs (e.g.: coumadin, warfarin)


NCT ID:

NCT00774436


Primary Contact:

Principal Investigator
James Eastham, MD
Memorial Sloan Kettering Cancer Center


Backup Contact:

N/A


Location Contact:

New York, New York 10065
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.